Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?

Should you add Vectura Group PLC (LON: VEC) and Circassia Pharmaceuticals PLC (LON: CIR) to your portfolio before GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Although GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has struggled to grow its net profit in recent years, that situation is set to change. Certainly, the pharmaceutical company is continuing to feel the pain of generic competition but, with considerable cost savings to come through over the next couple of years, its margins should pick up moving forward.

In fact, GlaxoSmithKline is set to overturn four years of a falling bottom line to post earnings growth of 11% in financial year 2016. That would be an impressive rate of growth, being around 50% higher than the growth rate of the wider index. And, with GlaxoSmithKline having a price to earnings (P/E) ratio of 16.9, it still offers good value for money for a highly diversified, financially sound pharmaceutical company. In fact, GlaxoSmithKline has a price to earnings growth (PEG) ratio of just 1.4, which indicates that its shares could move much higher over the medium to long term.

Of course, GlaxoSmithKline is one of many impressive pharmaceutical companies listed in the UK. For example, Vectura (LSE: VEC), the biotech respiratory specialist, is also expected to post much-improved financials over the next couple of years, with it set to turn from loss into profit in the current year. In fact, after racking up £48m in pretax losses in the last five years, Vectura is forecast to generate a pretax profit of £2.5m in the current year. And, looking ahead, its pretax profit is set to rise to £20m next year, which is gradually being priced in by the market.

As such, Vectura’s share price has risen by 38% already this year and, despite trading on a forward P/E ratio of 27.6, it still holds considerable appeal owing to a PEG ratio of just 0.2. Therefore, its share price growth could challenge that of GlaxoSmithKline moving forward.

Meanwhile, Circassia (LSE: CIR) is another pharmaceutical company with considerable potential. Its recent share placing was successful and allowed it to make two key acquisitions, with asthma specialist, Aerocrine, and chronic obstructive pulmonary disease stocks, Prosonix, being acquired for around £240m in cash. And, while the market has been rather subdued regarding the company’s progress (Circassia’s shares are up just 7.5% in the last year), Neil Woodford’s 13.5% stake is likely to help investor sentiment to improve moving forward.

Despite this, GlaxoSmithKline appears to be a better buy than both Circassia and Vectura. That’s at least partly because of its stronger financial standing, black bottom line (Circassia is set to remain a loss-making company over the next two years) and the fact that there is a clear catalyst to push GlaxoSmithKline’s share price higher, in terms of its appealing PEG ratio. In addition, GlaxoSmithKline has greater diversity than its two smaller sector peers and, while investor sentiment has been rather weak in recent years, a refreshed strategy and improving financial performance could enable its share to rise rapidly over the medium to long term.

So, while Circassia and, in particular, Vectura, are worth buying at the present time, GlaxoSmithKline appears to be the preferred option.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »